Evidence map›Paper›PMID 37106379›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance.

Wei-Juan Huang, Song-Bin Guo, Hui Shi, Xin-Ling Li, Yong Zhu, Mei Li, Li-Yan Song, Rong-Min Yu, Qing-Qing Cai, Xiao-Peng Tian

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Frontiers in cellular and infection microbiology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Wei-Juan Huang *Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Song-Bin Guo *Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Hui Shi *Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
Xin-Ling Li *Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
Yong Zhu *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Mei LiState Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li-Yan SongDepartment of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
Rong-Min YuDepartment of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
Qing-Qing CaiDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xiao-Peng TianDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. tianxp@sysucc.org.cn.
Jinan University · CNSun Yat-sen University · CNSun Yat-sen University Cancer Center · CNAnhui Medical University · CN

Funding

GuangDong Basic and Applied Basic Research Foundation 2023A1515012282National Natural Science Foundation of China 81603137National Natural Science Foundation of China 81973384National Natural Science Foundation of China 82270199
6 · The paper itself

Abstract

backgroundHigh-intensity chemotherapy regimens are often used in adult T-cell lymphoblastic lymphoma (T-LBL) patients. Nevertheless, the response rate remains unsatisfactory due to emergence of chemoresistance. Growing evidence has shown that long non-coding RNAs (lncRNAs) are involved in tumor progression and chemoresistance. Herein, we investigated the potential role of lncRNAs in T-LBLs.

methodsRNAseq was used to screen and identify candidate lncRNAs associated with T-LBL progression and chemoresistance. Luciferase reporter assay was used to examine the binding of miR-371b-5p to the 3'UTR of Smad2 and LEF1, and the binding of TCF-4/LEF1 to the promoter of LINC00183. Chromatin immunoprecipitation assay was undertaken to analyze the connection between LEF1 and the LINC00183 promoter region. RNA immunoprecipitation assays were used to explore the mechanism whereby LINC00183 regulated miR-371b-5p. MTT and flow cytometry assays were used to measure apoptosis of T-LBL cells.

resultsLINC00183 was upregulated in T-LBL progression and chemoresistant tissues in both the Sun Yat-sen University Cancer Center dataset and the First Affiliated Hospital of Anhui Medical University dataset. High expression of LINC00183 was correlated with poorer overall survival and progression-free survival of T-LBL patients compared to those with low expression of LINC00183. Furthermore, miR-371b-5p was negatively regulated by LINC00183. In vivo and in vitro assays showed that LINC00183-mediated T-LBL chemoresistance depended on miR-371b-5p expression. The direct binding of miR-371b-5p to Smad2 and LEF1 was verified by luciferase assays. It was shown that TCF4/LEF1 could bind to the LINC00183 promoter site and increase its transcript level. Downregulation of miR-371b-5p led to increased expression of Smad2/LEF1, and in turn increased LINC00183 expression. Additionally, phospho-Smad2 promotes nuclear translocation of β-catenin, LINC00183 downregulation decreased chemoresistance induced by β-catenin and TGF-β1 in T-LBL cells.

conclusionWe unraveled a β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 feedback loop that promotes T-LBL progression and chemoresistance, indicating that LINC00183 may serve as a potential therapeutic target in T-LBLs.

Indexed as

MicroRNAsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaRNA, Long NoncodingAdultbeta CateninCell Line, TumorCell ProliferationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansLymphoid Enhancer-Binding Factor 1Smad2 Proteinbeta CateninLEF1 protein, humanLymphoid Enhancer-Binding Factor 1MicroRNAsMIRN371 microRNA, humanRNA, Long NoncodingSmad2 ProteinSMAD2 protein, humanChemoresistanceLEF1LINC00183miR-371b-5pSmad2T-LBL

Identifiers

PMID37106379
PMCPMC10141948
OpenAlexW4367171915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.